Recent Updates
Recently added Catalysts

LY4100511

Phase 2

Plaque Psoriasis | Small molecule | Immunology |Eli Lilly and Company|Last Updated: Sep 12, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment222
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06602219A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque PsoriasisPHASE2 COMPLETED 222 — — Oct 25, 2024Sep 4, 2025Sep 12, 202558 United States, Canada +5
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75
Week 12
Secondary Endpoints
Percentage of Participants Achieving an sPGA Score of 0 (clear) or 1 (almost clear) with ≥2 grade Improvement from Baseline
Week 12
Percentage of Participants Achieving ≥50% Reduction in PASI score (PASI 50)
Week 12
Percentage of Participants Achieving ≥75% Reduction in PASI score (PASI 75)
Week 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
LY4100511 Dose 1EXPERIMENTALParticipants will receive LY4100511 orally.
LY4100511 Dose 2EXPERIMENTALParticipants will receive LY4100511 orally.
LY4100511 Dose 3EXPERIMENTALParticipants will receive LY4100511 orally.
PlaceboPLACEBO_COMPARATORPlacebo administered orally.
Interventions
NameTypeDescription
LY4100511DRUGAdministered orally
PlaceboDRUGAdministered orally
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites58

Inclusion Criteria: * Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization * Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive). * Must be willing to discontinue topical and/or systemic therapies for psoriasis before the fi...

Countries:United StatesCanadaCzechiaGermanyHungaryJapanPoland
Unlock Eligibility Criteria